Sartorius Opens New Plant in India
In a ribbon-cutting ceremony held on October 30, 2009, Sartorius (Goettingen, Germany) inaugurated its new plant at the Sartorius Group's location in Bangalore, India.
In a ribbon-cutting ceremony held on October 30, 2009, Sartorius (Goettingen, Germany) inaugurated its new plant at the Sartorius Group's location in Bangalore, India. The new facility is designed to supply the Indian marketplace and additional Asian markets.
CEO Joachim Kreuzburg, Arnold Picot, supervisory board chairman, and Amit Chatterjee, managing director of Sartorius India, officially started up operations at the large building complex. At its new site, Sartorius has combined its five decentralized individual locations in Bangalore into a single new plant on premises, thus creating new capacity for the company's Indian business in both Group divisions.
The company's expanded capacity in India enables it to create and develop new process technologies and to custom-tailor these to meet customers' individual process requirements, according to the company press release.
Among other products, Sartorius in Bangalore, India, develops and manufactures bioreactors and additional equipment for pharmaceutical customers, laboratory equipment, as well scales and other weighing equipment for industrial applications.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
